将年轻青少年纳入新型结核病疫苗政策制定
本文讨论将9-14岁年轻青少年纳入新型结核病疫苗政策制定的理由与挑战。支持因素包括在结核病风险年龄相关升高前接种、该年龄段HIV感染和妊娠率升高且均独立关联结核风险、以及可结合学校其他疫苗(如HPV疫苗)接种;挑战包括该年龄组结核病例累积率低、结核分枝杆菌致敏率低可能影响免疫保护关联桥接、以及模型显示相比高风险年龄组大规模接种人群影响有限。作者提出应在政策制定中明确考虑这些挑战以避免该人群被排除在直接获益之外,并描述一种利用近期家庭结核暴露后结核病例累积率更高的替代疗效试验设计。
要点
- 支持年轻青少年接种的理由包括在风险升高前接种及结合学校疫苗(如HPV)接种。
- 挑战包括该年龄组结核病例累积率低和结核分枝杆菌致敏率低影响免疫桥接。
- 建议在政策制定中明确考虑挑战,并采用家庭暴露后病例累积的替代试验设计。
核心结论
- 应在结核病疫苗政策制定中明确考虑年轻青少年纳入的挑战,避免其被排除在直接获益之外。
- 利用近期家庭结核暴露后病例累积率更高的替代疗效试验设计,可能支持新疫苗在年轻青少年中快速实施。
研究设计与样本
- 本文为政策分析与观点性文章,未报告原始研究样本量或系统检索方法。
主要发现
- 年轻青少年(9-14岁)历史上被排除在新型结核病疫苗临床试验之外。
- 该年龄组结核病例累积率低、结核分枝杆菌致敏率低,可能影响从成人桥接免疫保护关联。
- 模型显示年轻青少年接种的人群影响相比高风险年龄组大规模接种有限。
- 若仅对已感染结核分枝杆菌者有效的疫苗仅用于年轻青少年,其低人群影响可能多年难以检测。
关键数值与推荐
- 原文未报告具体数值、阈值或推荐条款。
临床怎么用
- 在结核病疫苗政策制定中应明确考虑年轻青少年纳入的挑战,避免其被排除在直接获益之外。
- 可探索利用近期家庭结核暴露后病例累积率更高的替代疗效试验设计,以获取疫苗效力和免疫保护关联验证数据。
- 结合学校其他疫苗接种(如HPV疫苗)可能为年轻青少年结核疫苗接种提供实施机会。
局限性
- 原文未报告研究设计的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The infant tuberculosis vaccine, BCG, prevents severe tuberculosis disease, but protection is rarely durable beyond childhood. New tuberculosis vaccines are being developed for the prevention of infectious pulmonary tuberculosis in older adolescents and adults, but younger adolescents have been historically excluded from clinical trials of new tuberculosis vaccines. Reasons to include young adolescents (aged 9-14 years) in tuberculosis vaccine policy development include the opportunity to vaccinate before the age-related increase in risk of tuberculosis disease, as well as increased rates of HIV acquisition and pregnancy, which are both independently associated with tuberculosis risk, and the opportunity to implement tuberculosis vaccination with delivery of other school-age vaccines, such as human papillomavirus. These advantages are offset by several challenges, including testing vaccine efficacy in an age group with low rates of tuberculosis case accrual; low rates of Mycobacterium tuberculosis sensitisation, which might compromise bridging of immune correlates of protection from adults; and modest modelled population impact of vaccination of young adolescents, compared with mass campaigns in older age groups with higher tuberculosis incidence. Notably, if a tuberculosis vaccine that was effective only in individuals who are infected with M tuberculosis was rolled out exclusively to young adolescents, the projected low population impact could take many years to detect. We propose that challenges to the inclusion of young adolescents should be considered explicitly in the development of tuberculosis vaccine policy, so that they do not risk exclusion from the direct benefits of vaccination. We describe an alternative efficacy trial design, which would leverage higher rates of tuberculosis case accrual after recent household tuberculosis exposure, to deliver both vaccine efficacy data and validation of an immune correlate of protection. This novel strategy, together with licensure data from older populations, might support rapid implementation of new, effective tuberculosis vaccines for young adolescents.
引用
- Hatherill M, Clark RA, Martinez L, et al. Inclusion of young adolescents in policy development for new tuberculosis vaccines. Lancet Glob Health. 2026. PMID: 42259345. doi:10.1016/S2214-109X(26)00017-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。